AI주식인사이트AI Stock Insight
C

압타머사이언스

291650KOSDAQ자연과학 및 공학 연구개발업

52.0 / 100

Reference Date: 2026-06-10

Financial Score23.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 50.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AptaMera Science is a biotech company spun off from POSTECH in 2011, specializing in the development of innovative therapeutics based on aptamer technology and offering CRO services for biopharmaceutical analysis. Utilizing its proprietary ApDC® platform, the company is advancing the development of targeted anti-cancer drugs for solid and hematologic malignancies, with key candidates like AST-201 and AST-202 in clinical trials, and expanded into CRO services in 2024.

Number of Employees

44people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
1.78Industry Average 3.245.5Point

Lower than industry avg (good)

ROE
-32.13Industry Average -32.093.5Point

In line with industry avg

Debt Ratio
3.91Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲284.5% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲15.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -45.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 823Won52-week high 1,94152-week low 684
1-month return0.0Point

1m -50.18% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral주주명부폐쇄기간또는기준일설정2026-05-21
  • Neutral주주총회소집결의 (임시주주총회)2026-05-21
  • Neutral분기보고서 (2026.03)2026-05-15